XPDc.934G>A polymorphism of nucleotide excision repair pathway in outcome of head and neck squamous cell carcinoma patients treated with cisplatin chemoradiation
Open Access
- 24 February 2016
- journal article
- research article
- Published by Impact Journals, LLC in Oncotarget
- Vol. 8 (10) , 16190-16201
Abstract
XPD c.934G>A polymorphism of nucleotide excision repair pathway in outcome of head and neck squamous cell carcinoma patients treated with cisplatin chemoradiationKeywords
This publication has 56 references indexed in Scilit:
- Human papillomavirus (HPV) 16 and the prognosis of head and neck cancer in a geographical region with a low prevalence of HPV infectionCancer Causes & Control, 2014
- Drug-Induced Oxidative Stress and ToxicityJournal of Toxicology, 2012
- Effect of Polymorphisms in XPD on Clinical Outcomes of Platinum-Based Chemotherapy for Chinese Non-Small Cell Lung Cancer PatientsPLOS ONE, 2012
- The evolution and mechanisms of nucleotide excision repair proteinsResearch in Microbiology, 2011
- Association of MDR1 and ERCC1 polymorphisms with response and toxicity to cisplatin-based chemotherapy in non-small-cell lung cancer patientsInternational Journal of Hygiene and Environmental Health, 2010
- Cisplatin pharmacogenetics, DNA repair polymorphisms, and esophageal cancer outcomesPharmacogenetics and Genomics, 2009
- Single nucleotide polymorphisms and outcome in docetaxel–cisplatin-treated advanced non-small-cell lung cancerAnnals of Oncology, 2004
- Assessment of Nucleotide Excision Repair XPD Polymorphisms in the Peripheral Blood of Gemcitabine/Cisplatin–Treated Advanced Non–Small-Cell Lung Cancer PatientsClinical Lung Cancer, 2003
- Comparison of two human ovarian carcinoma cell lines (A2780/CP70 and MCAS) that are equally resistant to platinum, but differ at codon 118 of the ERCC1 gene.International Journal of Oncology, 2000
- Randomized comparison of cisplatin plus fluorouracil and carboplatin plus fluorouracil versus methotrexate in advanced squamous-cell carcinoma of the head and neck: a Southwest Oncology Group study.Journal of Clinical Oncology, 1992